New Challenges in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 75
Special Issue Editors
Interests: clinical hematology; hematopoietic stem cell transplantation; acute leukemias; immunotherapy; mesenchymal stromal cells; stem cell biology; biostatistics
Interests: clinical hematology; hematopoietic stem cell transplantation; acute leukemias; graft versus host disease; immunotherapy
Special Issue Information
Dear Colleagues,
Almost 70 years after the first successful attempt in 1956, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently a fundamental treatment option for oncohematological diseases and the precursor of immunotherapy of neoplastic diseases. Its use in patients affected by acute myeloid leukemia (AML) can now be proposed up to old age thanks to major advancements in donor/host matching, pre-transplant conditioning, immunosuppressive therapy, and the prevention and management of infections.
Despite this, treatment-related mortality still ranges between 10 and 30%, mainly due to comorbidity, infectious complications, and the occurrence of graft-versus-host disease (GVHD). Even without these complications, long-term cure of AML is still achieved only in a minority of high-risk patients, as allo-HSCT loses effectiveness when the transplant is performed with active resistant disease, or in the case of genetically adverse, e.g., complex-karyotype or TP53-mutated leukemias.
It is becoming increasingly common, then, to consider allo-HSCT as an additional step, rather than the final act, of the complex journey to cure; post-transplant interventions, ranging from earlier tapering of immunosuppression to various forms of maintenance, are currently being tested to improve outcome. Finally, intense research is being made on the rescue treatment options for relapsing patients, including a second transplantation.
We are pleased to invite authors to contribute with reviews of the literature and other original clinical research on all these topics, especially on the use of allo-HSCT against chemorefractory high-risk AML, on the prevention of relapse after transplantation and the treatment of steroid-refractory GVHD. Biological studies regarding the reconstitution of the immune system following allo-HSCT, the mechanisms of persistence of leukemic stem cells (LSC), and the mechanisms of GVHD resistance to treatment are also welcome.
We look forward to receiving your contributions!
Dr. Federico Mosna
Dr. Irene Cavattoni
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute myeloid leukemia (AML)
- allogeneic hematopoietic stem cells transplantation (allo-HSCT)
- immunotherapy
- leukemic stem cells
- graft versus host disease (GVHD)
- infections in immunodepressed patients
- immune reconstitution
- post-transplant management
- long-term results
- clinical
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
